

Idiopathic pulmonary fibrosis (IPF)



Is a devastating condition

- barely 1/2 of patients surviving the 3 years

Carries a prognosis

- worse than that of many cancers.

1. King TE, Pardo A, Selman M: Idiopathic pulmonary fibrosis. Lancet 2011, 378:1949-61.
2. Ganesh Raghu et al :An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med Vol 183. pp 788–824, 2011
3. Spagnolo et al : Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges . Multidisciplinary Respiratory Medicine 2012, 7:42
4. Athol U. Wells, Ulrich Costabel et al: Challenges in IPF diagnosis, current management and future perspectives. Sarcoidosis ,vasculitis and diffuse lung diseases 2015; 32; Suppl. 1: 28-35
5. Ganesh Raghu et al :An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline , Am J Respir Crit Care Med Vol 192, Iss 2, pp e3–e19, Jul 15, 2015
6. Fidler, Lee et al: Diagnostic disparity of previous and revised American Thoracic Society guidelines for idiopathic pulmonary fibrosis/La disparité diagnostique entre les lignes directrices passées et révisées de l'American Thoracic Society à l'égard de la fibrose pulmonaire idiopathique .Canadian Respiratory Journal22.2 . 2015 : 86-90
7. <https://www.blf.org.uk/Page/IPF-patient-charter>

Suspicion of IPF

often months/years after the initial manifestations

The most common presenting symptoms

- dry cough
- exertional dyspnea

wrongly attributed to
smoking habits
or aging.



1. Flaherty KR et al: Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am J Respir Crit Care Med 2007, 175:1054–1060.
2. Thomeer M et al: Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study group: Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis. Eur Respir J 2008, 31:585–591
3. Spagnolo et al : Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges . Multidisciplinary Respiratory Medicine 2012, 7:42
4. Wells A. The revised ATS/ERS/JRS/ALAT diagnostic criteria for idiopathic pulmonary fibrosis (IPF) – practical implications. Respiratory Research 2013; 14 (Suppl 1): S2.
5. Athol U. Wells, Ulrich Costabel et al: Challenges in IPF diagnosis, current management and future perspectives. Sarcoidosis ,vasculitis and diffuse lung diseases 2015; 32; Suppl. 1: 28-35

IPF -Diagnostic challenges

Delay in diagnosis

Alternative diagnosis

IPF and other forms of ILD ?

Special conditions

Acute exacerbation of IPF

Unclassifiable ILD

Obtaining a surgical lung biopsy



LogIn | Recupereaza parola | ContNou

REGIS Registrul Național de Pneumopatii Interstițiale Difuze și Sarcoidoză

Home | Despre noi | PID: pentru medici | PID: pentru pacienți | Registrul național de PID și sarcoidoză | Evenimente | Media | Contact

REGIS
pentru medici

REGIS
pentru pacienți

**Pentru PACIENȚI:
totul despre
Pneumopatiile interstițiale difuze
(PID)**

[Click aici >>>](#)

Link-uri utile

wasog.org
sarcoidosisnetwork.org
pulmonaryfibrosis.org

Site sponsorizat de

CE ESTE REGIS?

Registrul Național de Pneumopatii Interstițiale Difuze și sarcoidoză este un proiect al Institutului de Pneumoftiziologie "Marius Nasta", în colaborare cu Secția de Pneumologie a Spitalului de Boli Infecțioase "Victor Babeș" din Timișoara. Această inițiativă este susținută de Grupul de lucru pentru pneumopatii interstițiale difuze și sarcoidoză din cadrul Societății Române de Pneumologie.



SRP
Societatea Română de PNEUMOLOGIE



Irina Strambu



Voicu Tudorache



Claudia Toma

RARE DISEASES

a challenging activity for physicians

